A large proportion of patients with haemophilia acquired HIV-I infection because of the use of commercial clotting factor concentrates that had not been virus inactivated.' As in other risk groups, HIV infection in patients with haemophilia often leads to deterioration of the immune system and results in AIDS with opportunistic infections.2 3 The progression of HIV infection in paediatric patients with haemophilia is evident but runs a slower course when compared with the progression in adult HIV infected patients with haemophilia.4 5 Paediatric AIDS is more often associated with bacterial infections than it is in AIDS in adults. 6 The efficacy of intravenous immunoglobulin (IVIG) in primary immunodeficiencies like agammaglobulinaemia and common variable immunodeficiency is well established. 7 The application of IVIG is largely safe with regard to the frequency of anaphylactic and nonanaphylactic reactions, as well as regarding the transmission ofinfectious agents. 8 During recent years, the use of IVIG has been extended to diseases in which a possible immunomodulatory effect of IVIG could be of advantage. Examples of this application of IVIG include the management of idiopathic thrombocytopenic purpura, Kawasaki syndrome, and certain forms of rheumatic disorders. 9 The use of IVIG in paediatric AIDS was first shown to be effective in 1986, resulting in a decreased number of bacterial infections and in an increase of CD4+ T cells.'0 A more recent multicentre trial studying IVIG application in symptomatic HIV disease in children showed a significantly increased time free of severe bacterial infections in the treatment arm, but no effect on mortality was observed." In the latter study patients with haemophilia were not included.
Therapeutic Thirty six male patients aged 6 to 19 years (mean age 14-8 years) fulfilled these criteria and were enrolled in the study. The patients or their parents gave their informed consent. For the evaluation matched controlled pairs of patients were formed. All pairs were matched by age and stage of HIV infection. One patient from each pair received IVIG and the other patient received observation only. Eleven pairs (22 patients) were randomly assigned to the treatment or the control group; in seven pairs (14 patients) the patients were assigned to one of the arms according to the patient's or his parents request to receive IVIG or to belong to the control group. At the time of entry no patient had previously been treated with IVIG or antiretroviral drugs.
IVIG APPLICATION
Patients on the treatment arm were given 0-4 g/ kg IVIG (Venimmun, Behringwerke AG) on four consecutive days followed by 0 3 g/kg IVIG at 14 day intervals. On average, the IVIG infusions lasted a mean (SD) of 2-9 (0-6) hours. The study was designed for an evaluation period of 24 months. According to the guidelines of the Bundesministerium fuer Frauen, Familie, Jugend und Gesundheit, of the Federal Republic of Germany, adverse effects were directly reported to the study centre and evaluated for the necessity of terminating the IVIG application. EVALUATION 
CRITERIA FOR THE EFFICACY OF IVIG
The major criteria for studying the effects of IVIG were the progression of disease stage according to the Brodt/Helm classification,'2 the incidence of infectious events and HIV associated thrombocytopenia (defined as a platelet count <I00x 109/l), and the CD4+ T cell count. In addition to the opportunistic infections fulfilling the AIDS case definition of the CDC, the following were also included as infectious events: fever of unknown origin for more than one week, recurrent diarrhoea of more than three stools per day for more than one week, herpes zoster, oral candidiasis, pneumonia, bronchitis, sinusitis, and otitis media. The Brodt/Helm classification was used because it does not take account of the patient's age. This is in contrast to the CDC classification system, which would have divided our study group into two different classifications (that is patients above and below 13 years of age) and thus would have complicated the comparison between the study arms. As shown in table 1, the Brodt/Helm classification was modified for this study by using the ratio of CD4+ T cells to lymphocytes (this is not the ratio of CD4+ T cells to CD8+ T cells), which has been shown to be a reliable prognostic indicator of immunological deterioration in HIV infection.5 13 During the study physical and laboratory examinations of the patients were performed at the entry and at three month intervals thereafter.
LABORATORY TESTS
The following laboratory tests were performed 
IgG concentration in sera of the control group were 22-16 (2-84) g/l at the entry and [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (2126) g/l at the last examination. Discussion To our knowledge this is the first prospective controlled study dealing with the efficacy of IVIG application in the early stages of HIV infection in haemophilic patients. The adverse reactions reported here that accompanied the administration of IVIG were of nonanaphylactic character, and did not lead to discontinuance of the study in any patient. Usually these side effects could be avoided by slowing down the infusion rate. These adverse reactions have been previously well described elsewhere. '6 17 This study was performed in haemophilic patients classified as having early stages of HIV infection. Patients already suffering from AIDS or AIDS related complex were excluded from the study in order to detect specifically whether there is a measurable therapeutic benefit with early use of this interventional regimen. As shown in table 2 there was a considerable progression of HIV disease in both groups during the 24 months. In the IVIG group seven of 18 patients (38%) worsened according to the Brodt/Helm classification compared with five of 18 patients (28%) in the control group. In each group one patient developed AIDS. The patient in the IVIG group died during the study, the patient in the control group died four weeks after completion of the study. In conclusion, any benefit of the IVIG treatment in delaying disease progression as assessed by the staging of the patients was not detectable. At the beginning of the study no patient received antiretroviral drugs or antibiotics. Due to immunological deterioration, and the in between established efficacy of zidovudine as an antiretroviral agent and of pentamidine for prophylaxis against P carinii pneumonia, these regimens were initiated in five patients. As these patients were rather equally distributed between the two groups, this should not lead to a major bias. We can not rule out, however, that the institution of these drugs outweighs a potential benefit of IVIG.
To date, there has been no published study dealing with IVIG application in HIV infection in haemophiliacs. Therefore the results must be compared with studies of IVIG treatment in other risk groups. The National Institutes of Health multicentre trial in children with vertically transmitted symptomatic HIV infection did not result in a lower mortality in the IVIG group." Other reports, however, showed appreciable improvement of neurological symptoms such as psychomotor development and other clinical symptoms, such as lymphoid interstitial hyperplasia not directly related to bacterial infections; unfortunately, these studies lacked a control group. 18 19 Bacterial infections are a major cause of illness in paediatric AIDS or AIDS related complex.6 20 21 In this study only mild infections occurred in both groups during the 24 months, with the exception of the one case of P carinii pneumonia. This may be due to the onset of the study in early stages of HIV This prospective, controlled study was conducted in order to evaluate the efficacy of IVIG in early stages of HIV infection in haemophilic patients. In conclusion, after 24 months no significant effect was detected in comparison with the control group as assessed by (1) the progression of HIV disease defined by the modified Brodt/Helm classification, (2) the number of infectious events and occurrence of HIV associated thrombocytopenia, and (3) the CD4+ T cell count. Whether there is a benefit of IVIG after manifestation of AIDS in haemophilic patients cannot be concluded from these data and needs further evaluation. 
